SANTA BARBARA, Calif.,
Oct. 31, 2013 /PRNewswire/ -- VG Life
Sciences, Inc. is a publicly traded (VGLS) biotechnology company
focused on developing treatments for patients suffering autoimmune
and infectious diseases.
(Logo:
http://photos.prnewswire.com/prnh/20131031/LA07859LOGO)
The United States Patent and Trademark Office has issued on
October 15, 2013 Patent No.: US
8,557,764 covering the VG Life Sciences' peptide VG1177 for
treating HIV infection. The VG1177 peptide prevents the survival of
pro-inflammatory cells under conditions where inflammation is
unwanted, thereby allowing the body's natural containment systems
to provide protection from harm.
The hallmarks of chronic HIV infections are chronic inflammation
and loss of CD4 T cells. Thus this patent may have important
implications for treating inflammation associated with HIV
infection and AIDS.
The patent will be issued to the University
of Colorado (CU) and has been licensed exclusively to VG
Life Sciences as a result of the invention filed by VG Life
Sciences' Lead Scientist, Dr. M. Karen
Newell Rogers, PhD, during her tenure at the University of Colorado Colorado Springs. Dr.
Newell Rogers is currently at
Texas A&M University College of
Medicine and Baylor Scott and White
Health Care.
The patent abstract reads as follows:
"The invention relates to methods for modulating the immune
function through targeting of CLIP molecules as well as gamma delta
T cells. The result is wide range of new therapeutic regimens for
treating, inhibiting the development of, or otherwise dealing with,
a multitude of illnesses and conditions, including autoimmune
disease, transplant and cell graft rejection, cancer, bacterial
infection, HIV infection, and AIDS, as well as novel methods of
diagnosis and of introducing a treatment regimen into a
subject."
John Tynan, VG Life Sciences'
President and CEO said, "First, this is a great recognition of Dr.
Newell Rogers' hard work and ground
breaking research. Second, this reflects our commitment to expand
and secure our IP portfolio."
About VG Life Sciences Inc.
Santa Barbara, California-based
VG Life Sciences Inc., formerly known as Viral Genetics, is a
biotechnology company working on discovering and developing drug
therapies for infectious diseases, cancer and many autoimmune
diseases. VGLS controls over 50 US and international patents and
patents pending protecting its exclusive biotech platform
technologies. For more information and upcoming events, visit
www.vglifesciences.com or find VG Life Sciences, Inc. on Facebook,
Twitter, and LinkedIn.
Safe Harbor Statement and Forward-Looking Statements
This news release may contain forward-looking statements
that involve risks and uncertainties associated with financial
projections, milestone timelines, clinical development, regulatory
approvals and other risks described by VG Life Sciences from time
to time in its periodic reports. None of VG Life Sciences' drug
compounds are approved by the US FDA or by any comparable
regulatory agencies elsewhere in the world. Therefore, there can be
no assurance that the forward-looking statements included in this
release will prove to be accurate. In light of the significant
uncertainties inherent in the forward-looking statements included
herein, the forward-looking statements should not be regarded as a
representation by VG Life Sciences or any other person that the
objectives and plans of VG Life Sciences will be achieved.
Contact:
Alexandria Sumner, Director of
Corporate Communications
VG Life Sciences, Inc.
Phone: (805) 679-6763
Email: asumner@vglifesciences.com
SOURCE VG Life Sciences, Inc.